Smart Hydrogel Uses Ultrasound to Balance ROS and Heal Diabetic Foot Ulcers

Diabetic foot ulcers affect roughly one-third of all diabetic patients and represent a leading cause of non-traumatic lower-limb amputation worldwide. The wound environment is hostile: persistent hyperglycemia fuels bacterial overgrowth, dysregulates immune responses, and sustains excessive reactive oxygen species (ROS) that prevent normal healing. Existing therapies rarely address all these barriers simultaneously, creating an urgent need for smarter wound-care strategies.

The research team designed a two-stage ROS 'lever' system encapsulated within diselenide-bond-containing liposomes (DSPE-Se-Se-PEG-NH₂). These nanoparticles—termed LHET NPs (~146 nm, PDI ~0.14, zeta potential −35 mV)—co-loaded ergothioneine (ET), thrombin, and the sonosensitizer HMME. When fibrinogen was added topically and ultrasound was applied (the FLHET hydrogel system), sonodynamic therapy (SDT) generated a surge of bactericidal ROS at the wound site. This oxidative burst cleaved the diselenide bonds, rupturing the liposomes and releasing thrombin, which catalyzed conversion of fibrinogen into a conformally fitting fibrin gel. The gel served as a sustained-release depot for ET.

Once ultrasound ceased, the second phase began: ET—an FDA-recognized antioxidant from edible mushrooms roughly 10× more potent than glutathione at equivalent concentrations—continuously scavenged residual ROS. Lower oxidative stress drove macrophage polarization from the pro-inflammatory M1 phenotype toward the reparative M2 phenotype. RNA sequencing of wound tissue confirmed immunomodulatory pathway shifts consistent with reduced inflammation and enhanced tissue remodeling. In vitro and in vivo experiments in streptozotocin-induced diabetic mouse models demonstrated accelerated wound closure, increased neovascularization (CD31/α-SMA staining), improved collagen deposition, and measurable restoration of peripheral nerve function—a frequently overlooked DFU complication.

The 'lever' metaphor is apt: the system deliberately tips ROS high during the antibacterial phase then tips it low during the repair phase, mimicking the biphasic ROS demands of normal wound biology. By making thrombin-triggered gelation contingent on the same ROS burst that performs sterilization, the design elegantly couples drug release to the therapeutic action rather than requiring separate administration steps.

While results are promising, the study remains preclinical, and the translation pathway to clinical DFU care—including scale-up of diselenide liposome synthesis, standardized ultrasound dosing protocols, and long-term safety data in humans—has yet to be established.